Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

AZ’s Galbraith to continue Baselga’s drive into new modalities 

New head of oncology R&D plans to put AstraZeneca on the cell therapy map

By Lauren Martz, Senior Editor
August 7, 2021 12:25 AM UTC

AstraZeneca’s new leader of oncology R&D Susan Galbraith plans to continue where predecessor José Baselga left off, driving the pharma’s oncology pipeline transformation into cell therapies and prioritizing early lines of treatment, while applying her eye for early-stage opportunities. 

An 11-year veteran of AstraZeneca plc (LSE:AZN; NYSE:AZN), Galbraith was appointed EVP of oncology R&D in late June, stepping into the role left vacant in March by the death of Baselga. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Astrazeneca plc

Daiichi Sankyo Co. Ltd.

Gilead Sciences Inc.